Institution
Primary Children's Hospital
Healthcare•Salt Lake City, Utah, United States•
About: Primary Children's Hospital is a healthcare organization based out in Salt Lake City, Utah, United States. It is known for research contribution in the topics: Population & Health care. The organization has 1770 authors who have published 2594 publications receiving 107857 citations. The organization is also known as: Intermountain Primary Children's Medical Center & Intermountain Primary Children's Hospital.
Topics: Population, Health care, Transplantation, Poison control, Medicine
Papers published on a yearly basis
Papers
More filters
TL;DR: A rabbit model was developed to investigate the histologic ultrastructure and rheologic properties of the scarred vocal fold lamina propria and the possible role of interstitial proteins in the etiology of increased stiffness and viscosity, which requires further investigation.
229 citations
Harvard University1, Johns Hopkins University2, University of Toronto3, Cornell University4, Duke University5, Primary Children's Hospital6, University of Pennsylvania7, National Institutes of Health8, Columbia University9, Medical University of South Carolina10, University of Texas Southwestern Medical Center11
TL;DR: In this article, the authors compared the effect of atenolol and losartan therapy on the rate of aortic root growth and other short-term cardiovascular outcomes in subjects with Marfan syndrome.
226 citations
TL;DR: The role of Axl and Mer in normal cellular function and their role in oncogenesis are elucidated and the potential to inhibit these RTKs for the development of therapeutic targets in treatment of cancer is reviewed.
Abstract: Receptor tyrosine kinases (RTK) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play an important role in signal transduction in both normal and malignant cells. The mammalian TAM RTK family includes 3 closely related members: Tyro-3, Axl, and Mer. Overexpression or ectopic expression of the TAM receptors has been detected in a wide array of human cancers. Growth arrest-specific gene 6 has been identified as the major ligand for these TAM RTKs, and its binding to the receptors has been shown to promote proliferation and survival of cancer cells in vitro. Abnormal expression and activation of Axl or Mer can provide a survival advantage for certain cancer cells. Inhibition of Axl and Mer may enhance the sensitivity of cancer cells to cytotoxic agents and would potentially be a therapeutic strategy to target cancer cells. This review elucidates the role of Axl and Mer in normal cellular function and their role in oncogenesis. In addition, we review the potential to inhibit these RTKs for the development of therapeutic targets in treatment of cancer.
219 citations
Institut Gustave Roussy1, University College London2, Mayo Clinic3, Sinai Grace Hospital4, Dresden University of Technology5, Primary Children's Hospital6, University of Melbourne7, University of Alabama at Birmingham8, Curie Institute9, Harvard University10, Medical Research Council11, Radiation Therapy Oncology Group12, Karolinska Institutet13, Maastricht University14
TL;DR: Patients with nonmetastatic NSCLC derived a significant OS benefit from accelerated or hyperfractionated radiotherapy; a similar but nonsignificant trend was observed for SCLC; as expected, there was increased acute esophageal toxicity.
Abstract: Purpose In lung cancer, randomized trials assessing hyperfractionated or accelerated radiotherapy seem to yield conflicting results regarding the effects on overall (OS) or progression-free survival (PFS). The Meta-Analysis of Radiotherapy in Lung Cancer Collaborative Group decided to address the role of modified radiotherapy fractionation. Material and Methods We performed an individual patient data meta-analysis in patients with nonmetastatic lung cancer, which included trials comparing modified radiotherapy with conventional radiotherapy. Results In non–small-cell lung cancer (NSCLC; 10 trials, 2,000 patients), modified fractionation improved OS as compared with conventional schedules (hazard ratio [HR] = 0.88, 95% CI, 0.80 to 0.97; P = .009), resulting in an absolute benefit of 2.5% (8.3% to 10.8%) at 5 years. No evidence of heterogeneity between trials was found. There was no evidence of a benefit on PFS (HR = 0.94; 95% CI, 0.86 to 1.03; P = .19). Modified radiotherapy reduced deaths resulting from l...
219 citations
TL;DR: An expert panel reviewed the results of TAILORx along with other published literature on the Oncotype DX assay to assess for evidence of clinical utility and recommends that oncologists may offer chemoendocrine therapy to patients with recurrence scores of 26 to 30.
Abstract: PURPOSEThis focused update addresses the use of Oncotype DX in guiding decisions on the use of adjuvant systemic therapy.METHODSASCO uses a signals approach to facilitate guideline updating. For th...
219 citations
Authors
Showing all 1777 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Scott Thomas | 131 | 1219 | 85507 |
| Michael R. Bristow | 113 | 508 | 60747 |
| Ikuo Ueda | 106 | 1053 | 48642 |
| David Robinson | 101 | 757 | 38372 |
| Pedram Argani | 97 | 372 | 35607 |
| Glenn D. Prestwich | 88 | 690 | 42758 |
| Melvin M. Scheinman | 86 | 531 | 25883 |
| John M. Opitz | 85 | 1193 | 40257 |
| George R. Saade | 82 | 872 | 30325 |
| James Neil Weinstein | 81 | 325 | 24918 |
| Michael Charlton | 79 | 333 | 28494 |
| James M. Ford | 79 | 314 | 20750 |
| Michael W. Varner | 74 | 405 | 19346 |
| Murray D. Mitchell | 74 | 540 | 20408 |
| Jeffrey L. Anderson | 73 | 300 | 25916 |